Introduction <p>Ovarian cancer significantly contributes to cancer-related deaths among women. Resistance to anchorage-dependent cell death (anoikis) plays a vital role in facilitating metastasis and worsening patient prognosis. Recent developments in the field of cancer biology have underscored the importance of long noncoding RNAs (lncRNAs) as crucial regulatory entities. However, their functions in the context of anoikis, particularly in ovarian cancer patients, remain inadequately understood.</p> Materials and methods <p>We conducted a comprehensive analysis of transcriptome data obtained from public databases, with a focus on screening lncRNAs associated with anoikis-related genes. A novel prognostic model that integrates risk scores to evaluate the predictive efficacy for patient outcomes was developed. We subsequently assessed the expression levels and functional role of the lncRNA BMPR1B-DT in ovarian cancer tissues through various techniques, including Western blot analysis, quantitative real-time polymerase chain reaction (qRT‒PCR), cell counting kit-8 (CCK‒8) assays, and flow cytometry.</p> Results <p>Our research demonstrates that the anoikis-related lncRNA prognostic model has significant clinical value in predicting the survival outcomes of ovarian cancer patients. Additionally, our study revealed that expression of the lncRNA BMPR1B-DT is upregulated in ovarian cancer tissues and cell lines. Moreover, we revealed that BMPR1B-DT promotes anoikis and inhibits proliferation under suspension culture conditions in ovarian cancer cells.</p> Conclusion <p>Our results suggest that BMPR1B-DT expression is critical in the process of anoikis in ovarian cancer patients. These insights underscore the necessity for further investigations aimed at translating these findings into clinical applications to improve diagnostic and therapeutic approaches for ovarian cancer patients.</p>